Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors

International Journal of Antimicrobial Agents

Volumn 20, Issue 6, 2002, Pages 438-443

  Barreiro, Pablo ^a   Camino, Nuria ^a   De Mendoza, Carmen ^a   Valer, Luisa ^a   Núñez, Marina ^a   Martín Carbonero, Luz ^a   González Lahoz, Juan ^a   Soriano, Vincent ^a,b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b NONE   (Spain)

Author keywords

Drug resistance; Protease inhibitors; Ritonavir; Salvage therapy

Indexed keywords

ABACAVIR; CD4 ANTIGEN; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TENOFOVIR; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EXPOSURE; FEMALE; GASTROINTESTINAL DISEASE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROLITHIASIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; VIROLOGY; VOMITING; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; GENETICS; MIDDLE AGED; SALVAGE THERAPY; TREATMENT OUTCOME;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; RITONAVIR; RNA, VIRAL; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0036891417     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(02)00250-9     Document Type: Article

References (37)

1. Palella F., Delaney K., Moorman A., et al. Declining morbidity and mortality among patients with advanced HIV infection. New Engl. J. Med. 338:1998;853-860.
2. Gulick R., Mellors J., Havlir D., et al. Treatment with indinavir, zidovudine and lamivudine in adults with HIV infection and prior antiretroviral therapy. New Engl. J. Med. 337:1997;734-739.
3. Carr A., Samaras K., Burton S., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 12:1998;F51-F58.
4. Friedman G., Andrews L. Adherence to antiretroviral therapy. AIDS Rev. 3:2001;111-120.
5. Ledergerber B., Egger M., Opravil M., et al. Clinical progression and virologic failure on HAART in HIV-1 patients: a prospective cohort study. Lancet. 354:1999;863-868.
6. Rodriguez-Rosado R., Jimenez-Nacher I., Soriano V., Anton P., Gonzalez-Lahoz. Virological failure and adherence to antiretroviral therapy in HIV-infected patients. AIDS. 12:1998;1112-1113.
7. Barry M., Gibbons S., Back D., Mulcahy F. Protease inhibitors in patients with HIV disease: clinically important pharmacokinetic considerations. Clin. Pharmacokinet. 32:1997;194-209.
8. Flexner C. HIV protease inhibitors. New Engl. J. Med. 338:1998;1281-1292.
9. Kumar G., Rodrigues A., Buko A., Denissen J. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 277:1996;423-431.
10. Kempf D., Marsh K., Kumar G., et al. Pharmacokinetic enhancement of inhibitors of the HIV protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:1997;654-660.
11. Kim R., Fromm M., Wandel C., et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:1998;289-294.
12. Van Praag R., Weverling G., Portegies P., et al. Enhanced penetration of indinavir in cerebrospinal fluid and semen after addition of low-dose ritonavir. AIDS. 14:2000;1187-1194.
13. Havlir D., Hellmann N., Petropoulos C., et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. J. Am. Med. Assoc. 283:2000;229-234.
14. Descamps D., Flandre P., Calvez V., et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. J. Am. Med. Assoc. 283:2000;205-211.
15. Gallego O., de Mendoza C., Perez-Elias M.J., et al. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. AIDS. 15:2001;1701-1706.
16. Condra J., Petropoulos C., Ziermann R., Schleif W., Shivaprakash M., Emini E. Drug resistance and predicted virologic response to HIV type 1 protease inhibitor therapy. J. Infect. Dis. 182:2000;758-765.
17. Kemp D., Isaacson J., King M., et al. Identification of genotypic changes in HIV-protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from PI-experienced patients. J. Virol. 75:2001;7462-7469.
18. Collins M., Irvine B., Tyner D., et al. A branched DNA signal amplification assay for quantitation of nucleic acid targets below 100 molecules/ml. Nucleic Acid Res. 25:1997;2979-2984.
19. Antiretroviral resistance mutations. HIV Clin. Trials. 2:2001;346-355. Revised April.
20. Rodríguez-Rosado R., Soriano V., Barreiro P., Dona C., González-Lahoz J. What dual protease inhibitor combination for salvage therapies? AIDS. 13:1999;2180-2181.
21. Zolopa A, Keiser P, Tebas P, et al. Predictors of response to ritonavir/saquinavir antiretroviral therapy in patients for whom nelfinavir failed: a multi-centered clinical cohort study. Proceedings of the Thirteenth International AIDS Conference, Durban, 2000 (abstract WePeB4173).
22. Chavanet P., Piroth L., Grappin M., et al. Randomized salvage therapy with saquinavir-ritonavir versus saquinavir-nelfinavir for highly protease inhibitor-experienced HIV-infected patients. HIV Clin. Trials. 2:2001;408-412.
23. Barreiro P., Soriano V., Oller V., González-Lahoz J. Potent activity but limited tolerance of ritonavir plus indinavir in salvage interventions. J. Acquir. Immune Defic. Syndr. 24:2000;488.
24. Rockstroh J, Lohrengel B, Rode R, Reitmayer R. Efficacy and safety results from the ABT-378/R early access program in Germany. Proceedings of the Eighth European Conference on Clinical Aspects and Treatment of HIV-Infection, Athens, 2001 (abstract P232).
25. Clotet B, Moreno S, González-Lahoz J, et al. Efficacy and safety results of lopinavir/r based HAART in expanded access program in Spain through W24. Proceedings of the Eighth European Conference on Clinical Aspects and Treatment of HIV-Infection, Athens, 2001 (abstract P235).
26. Gilleece Y, Qazi N, Pozniak A, Gazzard B, Nelson M. The efficacy of lopinavir in PI-failing regimes and the safety of switching from a non-failing antiretroviral regime to lopinavir. Proceedings of the Eighth European Conference on Clinical Aspects and Treatment of HIV-Infection, Athens, 2001 (abstract P60).
27. Germinario A, di Luzio U, Chevallier P. Initial efficacy and safety results from the lopinavir/ritonavir (ABT-378/R) early access program in Italy. Proceedings of the Eighth European Conference on Clinical Aspects and Treatment of HIV-Infection, Athens, 2001 (abstract P233).
28. Bonfanti P., Valsecchi L., Parazzini F., et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. J. Acquir. Immune Defic. Syndr. 23:2000;236-245.
29. Barreiro P., Soriano V., Cabello N., Gonzalez-Lahoz J. Is there a role for indinavir twice-daily in clinical practice? Clin. Microbiol. Infect. 6:2000;152-154.
30. Cahn P, Casiro A, Puentes T, et al. Continuing indinavir (800 mg tid) versus switching to indinavir plus ritonavir (800/100 mg bid) in HIV patients having achieved viral load suppression. A randomized study: the bid efficacy and safety trial. First IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, 2001 (abstract 60).
31. Burger D., Hugen P., Aarnoutse R., et al. A retrospective, cohort-based survey of patients using twice-daily indinavir+ritonavir combinations: pharmacokinetics, safety, and efficacy. J. Acquir. Immune Defic. Syndr. 26:2001;218-224.
32. trough inhibitory quotient predicts virologic response to ABT-378/ritonavir therapy in treatment experienced patients. AIDS. 14:(Suppl 14):2000;12.
33. Veldkamp A., van Heeswijk R., Mulder J., et al. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1 infected individuals. J. Acquir. Immune Defic. Syndr. 27:2001;344-349.
34. Nascimbeni M., Lamotte C., Peytavin G., Farinotti R., Clavel F. Kinetics of antiviral activity and intracellular pharmacokinetics of HIV type 1 protease inhibitors in tissue culture. Antimicrob. Agents Chemother. 43:1999;2629-2634.
35. Shafer R., Kantor R., Gonzales M. The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors. AIDS Rev. 2:2000;211-228.
36. Calvez V., Cohen-Codar I., Marcelin A., et al. Analysis of the correlation between baseline genotypic profile and virologic response to lopinavir/ritonavir in 104 multiple PI-experienced patients treated under Expanded Access Program. Antivir. Ther. 6:(Suppl 1):2001;69.
37. Masquelier B., Lawson-Ayayi S., Neau D., et al. HIV-1 genotypic determinants of the virologic response to lopinavir/ritonavir-containing therapy in PI-experienced patients. Antivir. Ther. 6:(Suppl 1):2001;84.